PREVIOUS ISSUE NEXT ISSUE
May 2016 MHE0516_CV1.jpg
Health execs: Advice I would give my younger selfLooking back on your career, what advice do you wish you had starting out? Here’s what our editorial advisory board said.
Impact of Medicare's expanded benzodiazepine coverageLike any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications—just a year after Medicare Part D extended its coverage to include them in 2012—has some wondering why so many of these drugs are being prescribed.
Will wearables and healthcare ever sync?Though technology companies are continuing to innovate in the wearable field, healthcare organizations are slow to adapt.
Five strategies that drive higher value careDoug Chaet, senior vice president, Provider Networks and Value-Based Solutions at Independence Blue Cross, shares five strategies that can help providers succeed in value-based reimbursement models.
Pharma coupons: pros and consDrug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.
Cardiovascular drugs: Current spending, future outlookCardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.
Blue Shield of California CEO shares ACO success secretsInsight from Paul Markovich, CEO, Blue Shield of California
PREVIOUS ISSUE NEXT ISSUE